Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4

Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54

Zhitong FinanceMay 2 04:55

Xencor Price Target Cut to $38.00/Share From $56.00 by BTIG

Xencor Price Target Cut to $38.00/Share From $56.00 by BTIG

Dow JonesApr 17 00:15

Xencor Is Maintained at Buy by BTIG

Xencor Is Maintained at Buy by BTIG

Dow JonesApr 17 00:15

BTIG: Maintaining the Xencor (XNCR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $56.00 to $38.00.

BTIG: Maintaining the Xencor (XNCR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $56.00 to $38.00.

Zhitong FinanceApr 17 00:11

BTIG Maintains Buy on Xencor, Lowers Price Target to $38

BTIG analyst Kaveri Pohlman maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $56 to $38.

BenzingaApr 17 00:04

Xencor Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 93.29% BTIG $56 → $38 Maintains Buy 02/28/2024 22.08% Piper Sandler $37 → $24 Downgrades Overwe

BenzingaApr 17 00:02